Sartorius is benefiting from the biopharmaceutical boom – and could make acquisitions

Frankfurt Almost 50 percent sales growth and 70 percent more adjusted profit: The Göttingen-based laboratory and pharmaceutical equipment supplier Sartorius can look back on an extraordinarily successful fiscal year. With this dynamic, the Dax newcomer clearly stands out in the leading index. However, a third of the growth is due to a special boom caused by the pandemic. Now the group has to prove that it can continue the good run in 2022.

At the annual general meeting next Friday, management will offer shareholders the prospect of double-digit growth rates for the years after the pandemic. Sartorius is focusing on the strongly growing basic business with the biopharmaceutical industry as a whole. For years, the company has benefited from the fact that more and more drugs are no longer produced chemically but biologically, for example with cell cultures in fermenters.